GENTIAN DIAGNOSTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.8 NOK | -2.07% |
|
-4.06% | -8.92% |
| Apr. 30 | Gentian Diagnostics ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 30 | Transcript : Gentian Diagnostics ASA, Q1 2024 Earnings Call, Apr 30, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 174M 16.07M | Sales 2025 * | 226M 20.8M | Capitalization | 595M 54.82M |
|---|---|---|---|---|---|
| Net income 2024 * | 7M 645K | Net income 2025 * | 13M 1.2M | EV / Sales 2024 * | 3.05 x |
| Net cash position 2024 * | 63M 5.8M | Net cash position 2025 * | 65M 5.99M | EV / Sales 2025 * | 2.35 x |
| P/E ratio 2024 * |
77.6
x | P/E ratio 2025 * |
44
x | Employees | 58 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.85% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gentian Diagnostics
More press releases
| Current month | -5.39% | ||
| 1 month | +7.22% | ||
| 3 months | -8.10% | ||
| 6 months | -4.69% | ||
| Current year | -6.99% |
1 week
38.00
40.20
1 month
34.8041.40
Current year
34.8044.00
1 year
34.8049.20
3 years
34.8086.00
5 years
34.8089.00
10 years
22.0089.00
| Managers | Title | Age | Since |
|---|---|---|---|
Njaal Kind
CEO | Chief Executive Officer | 52 | 18-01-01 |
Hilja Ibert
CHM | Chairman | - | 18-07-15 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Fredrik Thoresen
BRD | Director/Board Member | 44 | - |
| Director/Board Member | 60 | - | |
Kjersti Grimsrud
BRD | Director/Board Member | 63 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 37.8 | -2.07% | 6 812 |
| 24-05-10 | 38.6 | 0.00% | 4,356 |
| 24-05-08 | 38.6 | -1.53% | 4,017 |
| 24-05-07 | 39.2 | -0.51% | 100,863 |
| 24-05-06 | 39.4 | +2.07% | 3,261 |
Real-time Oslo Bors, May 13, 2024 at 04:33 am EDT
More quotes
Gentian Diagnostics ASA is a Norway-based company within health care sector. The Company develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Companyâs product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The Company is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.
Calendar
2024-08-29
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
38.6
NOK
Average target price
57
NOK
Spread / Average Target
+47.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.99% | 54.89M | |
| -2.04% | 12.64B | |
| -0.47% | 8.46B | |
| +9.02% | 5.66B | |
| +22.61% | 5.27B | |
| -2.03% | 4.49B | |
| -53.56% | 3.11B | |
| +19.30% | 2.87B | |
| +33.07% | 2.31B | |
| -3.55% | 1.89B |
- Stock Market
- Equities
- GENT Stock
